Psilocybin

DMT (N,N-Dimethyltryptamine) and its close relative 5-MeO-DMT are among the most potent psychedelics known, producing intense but brief experiences. N,N-DMT, found in many plants and the active component of ayahuasca, creates vivid geometric patterns, encounters with seemingly autonomous entities, and profound shifts in consciousness lasting 15-30 minutes when smoked or vaporized. 5-MeO-DMT, found naturally in certain plants and the venom of the Sonoran Desert toad (Incilius alvarius), produces a more unified, often ineffable "white light" experience characterized by ego dissolution and feelings of cosmic unity. Clinical research on 5-MeO-DMT has accelerated dramatically, with multiple Phase 1/2 trials active in 2024-2025. Beckley Psytech's Phase 2b trial of intranasal 5-MeO-DMT (BPL-003) for treatment-resistant depression showed rapid, durable antidepressant effects with MADRS reductions of 10.8-11.1 points at day 8, generally well-tolerated with no serious adverse events. Sublingual formulations are also in trials for anxiety and depression. Imperial College London reported that a single dose of ayahuasca's DMT compound produced significant and lasting depression relief in 2026 research. The rapid onset and short duration make DMT particularly interesting for clinical settings, as the entire experience can occur within a supervised session.

LSD (lysergic acid diethylamide) is a potent semi-synthetic psychedelic first synthesized by Albert Hofmann at Sandoz Laboratories in 1938. It activates serotonin 5-HT2A receptors, producing profound alterations in consciousness, perception, mood, and cognition lasting 8-12 hours. During the 1950s-60s, LSD showed remarkable promise in psychiatric research for treating alcoholism, anxiety, and enhancing psychotherapy before political backlash led to prohibition. Modern neuroscience reveals LSD increases brain network connectivity, particularly between regions that don't normally communicate, promoting cognitive flexibility and creative problem-solving. Unlike psilocybin, LSD has a longer duration and tends toward more geometric and abstract visual experiences. Recent clinical trials on LSD microdosing (10-20 μg doses, sub-perceptual) show it is safe in outpatient settings but lacks proven efficacy beyond placebo for core ADHD symptoms in a 2025 phase 2A trial. However, ongoing research explores LSD's potential for anxiety, depression, and cluster headaches. The compound's ability to induce ego dissolution and mystical experiences correlates with therapeutic benefits. Imperial College London pioneered modern LSD neuroimaging, revealing how it temporarily dissolves the brain's default mode network, allowing for psychological flexibility and new perspectives on entrenched problems.